PMID- 27653771
OWN - NLM
STAT- MEDLINE
DCOM- 20171002
LR  - 20181113
IS  - 2164-554X (Electronic)
IS  - 2164-5515 (Print)
IS  - 2164-5515 (Linking)
VI  - 12
IP  - 11
DP  - 2016 Nov
TI  - Lasting immune memory against hepatitis B in 12-13-year-old adolescents 
      previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV/Hib vaccine in 
      infancy.
PG  - 2916-2920
AB  - BACKGROUND: Vaccinating infants against hepatitis B virus (HBV) is the most 
      effective way of preventing the disease. However, since HBV exposure can increase 
      during adolescence, it is essential that antibody persistence is maintained. We 
      evaluated the antibody persistence and immune memory against hepatitis B, in 
      12-13 y olds who had received complete primary + booster vaccination with 
      diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated 
      poliovirus/Haemophilus influenza type b (DTPa-HBV-IPV/Hib) vaccine in infancy. 
      METHODS: Open phase-IV study conducted at 12 centers in Germany [NCT02052661]. 
      Adolescents aged 12-13 y, vaccinated with 4 doses of DTPa-HBV-IPV/Hib (Infanrix 
      hexa, GSK Vaccines) in infancy, received a single challenge dose of monovalent 
      pediatric hepatitis B vaccine (Engerix-B Kinder; GSK Vaccines). Blood samples 
      were taken before and 1-month post-challenge to measure anti-hepatitis B 
      (anti-HBs) antibodies using a chemiluminescence immunoassay (seroprotection 
      cut-off: >/=10 mIU/ml). Post-challenge adverse events (AEs) were monitored. 
      RESULTS: 300 subjects were vaccinated; of 293 subjects in the ATP immunogenicity 
      cohort, 60.5% had pre-challenge anti-HBs antibodies >/=10 mIU/ml, which rose to 
      97.6% post-challenge (>/=100 mIU/ml in 94.1%). An anamnestic response was seen in 
      96.5% subjects. A 150-fold increase in antibody geometric mean concentrations was 
      observed (22.4 to 3502.6 mIU/ml). Pain (44%) and fatigue (24.3%) were the most 
      frequent solicited local and general AEs, respectively; 14.7% subjects reported 
      unsolicited symptoms during the 31-day post-vaccination period. Two 
      vaccine-unrelated serious AEs occurred. CONCLUSION: Vaccination with 
      DTPa-HBV-IPV/Hib in infancy induces sustained seroprotection and immune memory 
      against HBV, as shown by the strong anamnestic response to the hepatitis B 
      vaccine challenge in 12-13 year-old adolescents.
FAU - Behre, Ulrich
AU  - Behre U
AD  - a Pediatric Practice , Kehl , Baden-Wurttemberg , Germany.
FAU - Van Der Meeren, Olivier
AU  - Van Der Meeren O
AD  - b GSK Vaccines , Wavre , Belgium.
FAU - Crasta, Priya
AU  - Crasta P
AD  - c GSK Vaccines , Bangalore , India.
FAU - Hanssens, Linda
AU  - Hanssens L
AD  - b GSK Vaccines , Wavre , Belgium.
FAU - Mesaros, Narcisa
AU  - Mesaros N
AD  - b GSK Vaccines , Wavre , Belgium.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160921
PL  - United States
TA  - Hum Vaccin Immunother
JT  - Human vaccines & immunotherapeutics
JID - 101572652
RN  - 0 (Diphtheria-Tetanus-Pertussis Vaccine)
RN  - 0 (Haemophilus Vaccines)
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Poliovirus Vaccine, Inactivated)
RN  - 0 (Vaccines, Combined)
RN  - 0 (diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus 
      influenzae b conjugate-hepatitis B vaccine)
SB  - IM
MH  - Adolescent
MH  - Age Factors
MH  - Child
MH  - Diphtheria-Tetanus-Pertussis Vaccine/*administration & dosage/*immunology
MH  - Female
MH  - Germany
MH  - Haemophilus Vaccines/*administration & dosage/*immunology
MH  - Hepatitis B/*prevention & control
MH  - Hepatitis B Antibodies/*blood
MH  - Hepatitis B Vaccines/*administration & dosage/*immunology
MH  - Humans
MH  - *Immunologic Memory
MH  - Male
MH  - Poliovirus Vaccine, Inactivated/*administration & dosage/*immunology
MH  - Vaccines, Combined/administration & dosage/immunology
PMC - PMC5137516
OTO - NOTNLM
OT  - Adolescents
OT  - DTPa-HBV-IPV/Hib
OT  - anamnestic response
OT  - challenge dose
OT  - hepatitis B
OT  - immune memory
OT  - long-term
OT  - persistence
OT  - seroprotection
EDAT- 2016/09/23 06:00
MHDA- 2017/10/03 06:00
PMCR- 2016/09/21
CRDT- 2016/09/23 06:00
PHST- 2016/09/23 06:00 [pubmed]
PHST- 2017/10/03 06:00 [medline]
PHST- 2016/09/23 06:00 [entrez]
PHST- 2016/09/21 00:00 [pmc-release]
AID - 1202388 [pii]
AID - 10.1080/21645515.2016.1202388 [doi]
PST - ppublish
SO  - Hum Vaccin Immunother. 2016 Nov;12(11):2916-2920. doi: 
      10.1080/21645515.2016.1202388. Epub 2016 Sep 21.